SANDOZ GROUP AG SPON ADS EACH REP 1 COM SHS(SDZNY.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
SANDOZ GROUP AG SPON ADS EACH REP 1 COM SHS
SDZNY.US
4.948 T
SDZNY.USMarket value -Rank by Market Cap -/-

Financial Score

28/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking46/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.64%C
    • Profit Margin2.14%C
    • Gross Margin45.79%B
  • Growth ScoreB
    • Revenue YoY4.71%C
    • Net Profit YoY2937.50%A
    • Total Assets YoY11.86%B
    • Net Assets YoY5.41%B
  • Cash ScoreB
    • Cash Flow Margin4663.88%A
    • OCF YoY4.71%C
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreD
    • Gearing Ratio59.18%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Berenberg Revises Sandoz Group Price Target, Estimates on Pipeline Potential

    Berenberg Revises Sandoz Group Price Target, Estimates on Pipeline Potential

    marketscreener·
    US
    SDZNY
    +3.59%
    marketscreener·
    US
    SDZNY
    +3.59%

    How Investors May Respond To Sandoz Group (SWX:SDZ) Winning EU Approval For Ondibta Biosimilar Insulin

    Sandoz Group has received EU approval for Ondibta®, a biosimilar insulin, enhancing its position in diabetes care. This approval is expected to broaden access to insulin in Europe, although the product launch is not anticipated until early 2027. Investors are encouraged to consider Sandoz's potential for growth against current financial pressures and high earnings multiples. The stock is viewed as potentially undervalued by 43%, with fair value estimates ranging significantly among analysts. The approval adds a long-term growth option but also increases execution risks amid a busy biosimilar launch schedule.

    Simplywall·
    US
    SDZNY
    +3.59%
    Simplywall·
    US
    SDZNY
    +3.59%

    Berenberg Bank Sticks to Their Hold Rating for Sandoz Group Ltd (SDZXF)

    Berenberg Bank has maintained a Hold rating for Sandoz Group Ltd (SDZXF) with a price target of CHF55.00, while the shares closed at CHF62.20. The analyst consensus for Sandoz is Moderate Buy, with a price target of CHF60.51, indicating a potential downside of 2.72%. Additionally, TipRanks also reiterated a Hold rating with a CHF65.00 price target.

    Tip Ranks·
    US
    SDZNY
    +3.59%
    Tip Ranks·
    US
    SDZNY
    +3.59%
    © 2026 Longbridge｜Disclaimer